No5 barrister at the head of the debate on pricing of rare drugs

Wed, 17 Nov 2010

No5 barrister David Lock is quoted in this week’s edition of the British Medical Journal in connection with the controversy over the pricing of rare drugs, which has seen 20 leading doctors write in protest to the Prime Minister about the conduct of drug companies.
 
Drug companies are attempting to persuade the NHS to prescribe expensive drugs which have an EU “marketing authorisation” in preference to much cheaper, generic drugs which have a similar clinical effect but have no marketing authorisation.
 
David has given advice to the NHS, which the NHS then chose to publish, that it would be likely to be lawful for NHS bodies to refuse to allow doctors to prescribe branded drug where there is a generic drug which delivers similar clinical outcomes at a lower cost. 
 
 

Related articles

Personal Injury analysis: This analysis considers Master Cook’s judgment in RXK in which he sets out the circumstances in which the court will order an interim payment despite final quantification still being some years hence. It explains why this will be welcome news for claimant solicitors, even though no substantive decision was given in the case....

Date: Wed, 04 Dec 2019
No5 Barristers’ Chambers joined forces with Moore Blatch Solicitors to host an “inspiring evening” to mark the centenary of women in law....

Date: Thu, 28 Nov 2019
In her article published today in the New Law Journal, “Duty of care: Inadequate safety nets?"...

Date: Fri, 19 Jul 2019